Advanced Prostate Cancer VL

Assessment of Simplified Methods for Quantification of 18F FDHT Uptake Scans in Patients with Metastasized Castrate-Resistant Prostate Cancer - Gem Kramer

(Length of Presentation: 8 min) This presentation represents a study performed to assess if [18F]FDHT PET/CT could be a valuable imaging biomarker in patients with prostate cancer. Biographies: Gem Kramer, Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands Read the Full Video Transcript

Current State of Liquid Biopsies in Prostate Cancer - Gert Attard

(Length of Interview: 13 min) Charles Ryan and Gert Attard discuss what is currently being done with regards to serum analysis, plasma analysis, liquid biopsies, circulating tumor cells, in the field of prostate cancer. Biographies: Professor Gerhardt Attard MD Ph.D. FRCP Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He...

PSMA Imaging and Theranostics: Future Impact to Patient Management– Robert Flavell

(Length of presentation: 30 min) In an interview with Phil Koo, Robert Flavell describes diagnostic and therapeutic applications of new agents in the management of patients with prostate cancer with initial high-risk diagnosis and biochemical recurrence. Biographies: Robert R. Flavell, MD, Ph.D., Assistant Professor in Residence Department of Radiology, Section of Nuclear Medicine, University of C...

Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro

(Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...

The United States Preventive Services Task Force PSA Screening Recommendations- David Penson

(Length of Discussion: 10 min) David Penson and Alicia Morgans share views on the evolution of the United States Preventive Services Task Force, USPSTF's recommendations for PSA screening. What do the recent changes mean to the clinician and the patient when making individual decisions regarding screening. Biographies: David F. Penson, MD, MPH, is the Paul V. Hamilton, M.D. and Virginia E. Howd Ch...

Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer (mCRPC) for Black versus White Men-Susan Halabi

(Length of Discussion: 12 min) Susan Halabi, the first biostatistician to become a fellow of ASCO, discusses recent data on overall survival in prostate cancer for black versus white men with Alicia Morgans and Charles Ryan. Susan discusses an analysis that showed an increase in overall survival in African American men vs Caucasian men, all of whom had metastatic castration-resistant prostate canc...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.